Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD

MT Newswires Live07-17

Kalaris Therapeutics (KLRS) said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.

The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients in the safety cohort, with all 20 patients completing six months of follow-up, according to the company.

Kalaris said the expanded efficacy analysis showed "robust" structural and functional improvements, and no cases of intraocular inflammation were noted among six patients treated with the 2.5 mg dose using product manufactured after process adjustments to reduce impurities.

The company said it continues to enroll and dose patients in an ongoing phase 1b/2 study evaluating a standard four-dose loading regimen of TH103 in treatment-naive patients using an ascending-dose design.

Kalaris said it expects to report initial data from the phase 1b/2 study in H1 of 2027.

Shares of Kalaris Therapeutics were down more than 8% in premarket activity Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652940075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652940075","market":"hk","top_or_hot":-1,"title":"Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD","media":"MT Newswires Live","content":"<html><body><p> Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KLRS) said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.</p><p>The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients in the safety cohort, with all 20 patients completing six months of follow-up, according to the company.</p><p>Kalaris said the expanded efficacy analysis showed \"robust\" structural and functional improvements, and no cases of intraocular inflammation were noted among six patients treated with the 2.5 mg dose using product manufactured after process adjustments to reduce impurities.</p><p>The company said it continues to enroll and dose patients in an ongoing phase 1b/2 study evaluating a standard four-dose loading regimen of TH103 in treatment-naive patients using an ascending-dose design.</p><p>Kalaris said it expects to report initial data from the phase 1b/2 study in H1 of 2027.</p><p>Shares of Kalaris Therapeutics were down more than 8% in premarket activity Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-17 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KLRS) said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.</p><p>The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients in the safety cohort, with all 20 patients completing six months of follow-up, according to the company.</p><p>Kalaris said the expanded efficacy analysis showed \"robust\" structural and functional improvements, and no cases of intraocular inflammation were noted among six patients treated with the 2.5 mg dose using product manufactured after process adjustments to reduce impurities.</p><p>The company said it continues to enroll and dose patients in an ongoing phase 1b/2 study evaluating a standard four-dose loading regimen of TH103 in treatment-naive patients using an ascending-dose design.</p><p>Kalaris said it expects to report initial data from the phase 1b/2 study in H1 of 2027.</p><p>Shares of Kalaris Therapeutics were down more than 8% in premarket activity Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2652940075","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652940075","pubTimestamp":1784288672,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kalaris Therapeutics  said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients in the safety cohort, with all 20 patients completing six months of follow-up, according to the company.Kalaris said the expanded efficacy analysis showed \"robust\" structural and functional improvements, and no cases of intraocular inflammation were noted among six patients treated with the 2.5 mg dose using product manufactured after process adjustments to reduce impurities.The company said it continues to enroll and dose patients in an ongoing phase 1b/2 study evaluating a standard four-dose loading regimen of TH103 in treatment-naive patients using an ascending-dose design.Kalaris said it expects to report initial data from the phase 1b/2 study in H1 of 2027.Shares of Kalaris Therapeutics were down ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KLRS":"Kalaris Therapeutics Inc."},"translate_title":"Kalaris 表示，在新生血管性 AMD 的 1a 期试验中，更多患者显示出视力改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLRS":1.97},"content_text":"Kalaris Therapeutics (KLRS) said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients in the safety cohort, with all 20 patients completing six months of follow-up, according to the company.Kalaris said the expanded efficacy analysis showed \"robust\" structural and functional improvements, and no cases of intraocular inflammation were noted among six patients treated with the 2.5 mg dose using product manufactured after process adjustments to reduce impurities.The company said it continues to enroll and dose patients in an ongoing phase 1b/2 study evaluating a standard four-dose loading regimen of TH103 in treatment-naive patients using an ascending-dose design.Kalaris said it expects to report initial data from the phase 1b/2 study in H1 of 2027.Shares of Kalaris Therapeutics were down more than 8% in premarket activity Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652940075","isCrawlerRequest":true}